Cost, coverage gaps and side effects often push people off GLP-1s, and News-Medical covers research on whether follow-up support helps keep weight from returning.
Recap by typeshit. Full story at News-Medical.
Pratt, a psychology professor who studies the circuits behind food motivation, walks through what neuroscience shows about these drugs.
Lilly's pill had major heart events in 4.2% of patients vs 5.0% on insulin glargine. The Clinical Trial Vanguard argues rivals now need to show benefit, not just safety.
A Future Health & Medical Innovation panel weighs how much of the growing interest in peptides and exosomes is backed by evidence.
The aging doctor shares a headline saying new studies point to GLP-1 drugs slowing the biological clock, and notes himself that more research is needed.
Activist investor Elliott pushed for targets at PepsiCo, and Reuters reports the clock is ticking while GLP-1 drugs weigh on snack demand.
She tells Fierce Pharma that drugmakers need new marketing playbooks, and Novo CEO Mike Doustdar explains the thinking behind the company's recent rebrand.
Loading…